CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Gastric mucosa protection in patients treated with iressa and COX-2 inhibitors in malignancies
DOI 10.1055/s-2004-827106
Bibliografische Angaben
Nachweis in CareLit
Autor:innenB Aladics, K Oreskovich, E Schafer, T Gyökeres, J Hamvas, J Moldvay, J Strausz, R Schwab, Á Pap
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe05/2004
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Gefitinib (ZD1893, Iressa) is an orally active, selective EGFR tyrosine-kinase inhibitor recently approved for the treatment of non-small cell lung cancer (NSCLC) by the FDA. At present, this drug represents one of the most attractive perspectives for the therapy of advanced stage patients especially with brain metastases, who are not eligible for conventional chemotherapy. Also COX-2 inhibitors have bee…
Zitieren
Zitierempfehlung
B Aladics, K Oreskovich, E Schafer, T Gyökeres, J Hamvas, J Moldvay, J Strausz, R Schwab, Á Pap (2004) Gastric mucosa protection in patients treated with iressa and COX-2 inhibitors in malignancies. Zeitschrift für Gastroenterologie (05). https://doi.org/10.1055/s-2004-827106
Mit CareLit weiterarbeiten